PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages – a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation
Open accessThe DOI matches its Crossref record; 61 of the 63 references it cites were found in a registry or an index.
Abstract
Background and objectives: Progesterone is essential to maintain a healthy pregnancy. Guidance from the Royal College of Obstetricians and Gynaecologists and a Cochrane review called for a definitive trial to test whether or not progesterone therapy in the first trimester could reduce the risk of miscarriage in women with a history of unexplained recurrent miscarriage (RM). The PROMISE trial was conducted to answer this question. A concurrent cost-effectiveness analysis was conducted. Design and setting: A randomised, double-blind, placebo-controlled, international multicentre study, with economic evaluation, conducted in hospital settings across the UK (36 sites) and in the Netherlands (nine sites). Participants and interventions: Women with unexplained RM (three or more first-trimester losses), aged between 18 and 39 years at randomisation, conceiving naturally and giving informed consent, received either micronised progesterone (Utrogestan®, Besins Healthcare) at a dose of 400 mg (two vaginal capsules of 200 mg) or placebo vaginal capsules twice daily, administered vaginally from soon after a positive urinary pregnancy test (and no later than 6 weeks of gestation) until 12 completed weeks of gestation (or earlier if the pregnancy ended before 12 weeks). Main outcome measures: Live birth beyond 24 completed weeks of gestation (primary outcome), clinical pregnancy at 6–8 weeks, ongoing pregnancy at 12 weeks, miscarriage, gestation at delivery, neonatal survival at 28 days of life, congenital abnormalities and resource use. Methods: Participants were randomised after confirmation of pregnancy. Randomisation was performed online via a secure internet facility. Data were collected on four occasions of outcome assessment after randomisation, up to 28 days after birth. Results: A total of 1568 participants were screened for eligibility. Of the 836 women randomised between 2010 and 2013, 404 received progesterone and 432 received placebo. The baseline data (age, body mass index, maternal ethnicity, smoking status and parity) of the participants were comparable in the two arms of the trial. The follow-up rate to primary outcome was 826 out of 836 (98.8%). The live birth rate in the progesterone group was 65.8% (262/398) and in the placebo group it was 63.3% (271/428), giving a relative risk of 1.04 (95% confidence interval 0.94 to 1.15;p = 0.45). There was no evidence of a significant difference between the groups for any of the secondary outcomes. Economic analysis suggested a favourable incremental cost-effectiveness ratio for decision-making but wide confidence intervals indicated a high level of uncertainty in the health benefits. Additional sensitivity analysis suggested the probability that progesterone would fall within the National Institute for Health and Care Excellence’s threshold of £20,000–30,000 per quality-adjusted life-year as between 0.7145 and 0.7341. Conclusions: There is no evidence that first-trimester progesterone therapy improves outcomes in women with a history of unexplained RM. Limitations: This study did not explore the effect of treatment with other progesterone preparations or treatment during the luteal phase of the menstrual cycle. Future work: Future research could explore the efficacy of progesterone supplementation administered during the luteal phase of the menstrual cycle in women attempting natural conception despite a history of RM. Trial registration: Current Controlled Trials ISRCTN92644181; EudraCT 2009-011208-42; Research Ethics Committee 09/H1208/44. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 41. See the NIHR Journals Library website for further project information.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant differences were observed in the former trial but not in the latter trial.”
From Recurrent MiscarriageGreen‐top Guideline No. 17 (2023) · cites this paper as [201]
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
An Efficient Method of Estimating Seemingly Unrelated Regressions and Tests for Aggregation Bias
Zellner, A. (1962) · Journal of the American Statistical Association · doi:10.1080/01621459.1962.10480664 · Cited by 8,401
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634 · cited 1×
“l A guideline by the RCOG and a Cochrane review called for a definitive trial to evaluate this research question.(12) l Participants in two unpublished surveys [one of women with RM (n= 88) and the other of gynaecologists (n= 102) treating women with RM] demonstrated an interest in progesterone therapy and a willingne…”
MethodA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood safer: 2006–2008
(2011) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2010.02847.x · Cited by 2,994
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538 · cited 1×
“One example of weak methodology was in lack of concealment, which has been shown to exaggerate effect sizes by up to 41%,(12) although there is some evidence that this exaggeration may not be a concern when the outcome is objective.(13) Small sample sizes increase the likelihood of random error (generating the wide CI…”
Equipoise and the Ethics of Clinical Research
Freedman, B. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707163170304 · Cited by 2,339
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Prevention of recurrent preterm delivery by 17 alpha–hydroxyprogesterone caproate
Meis, P. J., Klebanoff, M., Thom, E., Dombrowski, M. P., Sibai, B., Moawad, A. H., Spong, C. Y., Hauth, J. C., Miodovnik, M., Varner, M. W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035140 · Cited by 1,555
Rai, R., & Regan, L. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69204-0 · Cited by 1,227
Self-citationDeclaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
World Medical Association (WMA) (2009) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/9783110208856.233 · Cited by 1,087
Progesterone and the Risk of Preterm Birth among Women with a Short Cervix
Fonseca, E. B., Celik, E., Parra, M., Singh, M., & Nicolaides, K. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067815 · Cited by 1,086
da Fonseca, E. B., Bittar, R. E., Carvalho, M. H. B., & Zugaib, M. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.41 · Cited by 789 · cited 3×
“Furthermore, studies of vaginal progesterone in the prevention of preterm birth have shown its effectiveness when given via this route.(19,21,22) Therefore, we believe that any alternative preparation or route of administration is unlikely to result in a greater effect.”
BackgroundMethodCytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study
Stephenson, M. D. (2002) · Human Reproduction · doi:10.1093/humrep/17.2.446 · Cited by 522
Repeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · The British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 517 · cited 1×
“Under these conditions, no adjustment to the overall level of significance was needed.(55,56) Long-term analyses Although the development of the babies born to participants in the PROMISE trial was of interest to the investigators, this was outside the scope and time frame of the study.”
BackgroundCampbell, M., Snowdon, C., Francis, D., Elbourne, D., McDonald, A., Knight, R., Entwistle, V, Garcia, J., Roberts, I., Grant, A., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11480 · Cited by 433
Lay perspectives: advantages for health research
Entwistle, V. A., Renfrew, M. J., Yearley, S., Forrester, J., & Lamont, T. (1998) · BMJ · doi:10.1136/bmj.316.7129.463 · Cited by 376 · cited 1×
“Patient and public involvement (PPI) in research is not only a moral imperative (in consideration of the rights of service users and taxpayers to be involved in activities commissioned for them by government) but also a practical opportunity to ensure relevance, feasibility and accuracy.(62,63) Recognition of the impo…”
BackgroundThe use of QALYs in health care decision making
Loomes, G., & McKenzie, L. (1989) · Social Science & Medicine · doi:10.1016/0277-9536(89)90030-0 · Cited by 374
A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage
Brigham, S. A., Conlon, C., & Farquharson, R. G. (1999) · Human Reproduction · doi:10.1093/humrep/14.11.2868 · Cited by 365
Self-citationDodd, J. M., Jones, L., Flenady, V., Cincotta, R., & Crowther, C. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004947.pub3 · Cited by 331 · cited 1×
“For example, 14 out of 36 studies of second- and/or third-trimester progesterone to prevent preterm birth (identified by a recent systematic review) used vaginal progesterone, with significant improvements being observed for various clinical outcomes, confirming the biological effects of vaginal progesterone.(38)”
MethodLuteal phase support in infertility treatment: a meta-analysis of the randomized trials
Pritts, E. A. (2002) · Human Reproduction · doi:10.1093/humrep/17.9.2287 · Cited by 313
British National Formulary: BNF
Press, P. (2015) · doi:10.18578/bnf.147942626 · Cited by 269
Targeted drug delivery in gynaecology: the first uterine pass effect
Bulletti, C., de Ziegler, D., Flamigni, C., Giacomucci, E., Polli, V., Bolelli, G., & Franceschetti, F. (1997) · Human Reproduction · doi:10.1093/humrep/12.5.1073 · Cited by 245 · cited 2×
“Our choice to use the vaginal route of administration was, therefore, rational to deliver a greater proportion of drug to the relevant site (the uterus) using the ‘first uterine pass’ effect.(36,37) Furthermore, studies that have used vaginal progesterone in the prevention of preterm birth have reported its effectiven…”
MethodProgestogen for preventing miscarriage
Oates-Whitehead, R., Haas, D., & Carrier, J. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003511 · Cited by 224
Interim Analyses in Randomized Clinical Trials: Ramifications and Guidelines for Practitioners
Geller, N. L., & Pocock, S. J. (1987) · Biometrics · doi:10.2307/2531962 · Cited by 200 · cited 1×
“Under these conditions, no adjustment to the overall level of significance was needed.(55,56) Long-term analyses Although the development of the babies born to participants in the PROMISE trial was of interest to the investigators, this was outside the scope and time frame of the study.”
BackgroundStatistical properties of randomization in clinical trials
Lachin, J. M. (1988) · Controlled Clinical Trials · doi:10.1016/0197-2456(88)90045-1 · Cited by 200
The Economic Consequences of Preterm Birth Duringthe First 10 Years of Life
Petrou, S. (2005) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2005.00577.x · Cited by 197
Fetal genital effects of first-trimester sex hormone exposure: A meta-analysis
Raman-Wilms, L. (1995) · Obstetrics & Gynecology · doi:10.1016/0029-7844(94)00341-a · Cited by 195 · cited 1×
“A systematic review of observational studies (both cohort and case–control studies) of first-trimester sex hormone exposure identified 14 studies, comprising 65,567 women.(17) The sex hormone in several of these studies was progestogens alone or with other steroids.”
BackgroundThe role of luteal phase support in infertility treatment: a meta-analysis of randomized trials
Soliman, S., Salim Daya, M. B., Collins, J., & Hughes, E. G. (1994) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56758-2 · Cited by 194
Hanley, B., Truesdale, A., King, A., Elbourne, D., & Chalmers, I. (2001) · BMJ · doi:10.1136/bmj.322.7285.519 · Cited by 184 · cited 1×
“Patient and public involvement (PPI) in research is not only a moral imperative (in consideration of the rights of service users and taxpayers to be involved in activities commissioned for them by government) but also a practical opportunity to ensure relevance, feasibility and accuracy.(62,63) Recognition of the impo…”
BackgroundMaternal Progestin Intake and Risk of Hypospadias
Carmichael, S. L., Shaw, G. M., Laurent, C., Croughan, M. S., Olney, R. S., & Lammer, E. J. (2005) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.159.10.957 · Cited by 166 · cited 1×
“Most of the evidence in our review did not show harm, particularly any external genital malformation in the offspring, but one case–control study suggested an association between hypospadias and progestogen use.(18) Although findings from a case–control study represented weaker evidence than the better-quality evidenc…”
ResultMedicines for human use (clinical trials) regulations 2004.
(2004) · PubMed · Cited by 161
Quality of life in pre-adolescence: A 17-dimensional health-related measure (17D)
Apajasalo, M., Rautonen, J., Holmberg, C., Sinkkonen, J., Aalberg, V., Pihko, H. S., Siimes, M. A., Kaitila, I., M�kel�, A. L., Erkkil�, K., et al. (1996) · Quality of Life Research · doi:10.1007/bf00439227 · Cited by 152 · cited 1×
“It estimated QALYs up to 4 years of age using the 17-dimension parental questionnaire, reported with expected variations in the 4-year QALY by gestational age at birth.(74)”
MethodDAYA, S. (1989) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1989.tb02386.x · Cited by 134
Dydrogesterone in the reduction of recurrent spontaneous abortion
El-Zibdeh, M. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.08.007 · Cited by 118
Endocrinological and endometrial factors in recurrent miscarriage
Li, T. C., Spuijbroek, M. D. E. H., Tuckerman, E., Anstie, B., Loxley, M., & Laird, S. (2000) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2000.tb11670.x · Cited by 115
Self-citationLuteal Phase Support in in vitro Fertilization: Meta-Analysis of Randomized Trials
Nosarka, S., Kruger, T., Siebert, I., & Grové, D. (2005) · Gynecologic and Obstetric Investigation · doi:10.1159/000084546 · Cited by 96 · cited 2×
“For example, progesterone vaginal capsules are commonly used for luteal support in assisted conception at a treatment dose of 400mg twice daily, with no specific safety concerns raised on this dose.(16,32)”
BackgroundMethodProgestogen for preventing miscarriage
Haas, D. M., & Ramsey, P. S. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003511.pub2 · Cited by 94
Double-Blind Trial of a Progestin in Habitual Abortion
Goldzieher, J. W. (1964) · JAMA · doi:10.1001/jama.1964.03060330031008 · Cited by 93
Petrou, S., Trinder, J., Brocklehurst, P., & Smith, L. (2006) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.00998.x · Cited by 87 · cited 1×
“5% time discount rate was adopted to estimate values for the 2011–12 price year.(69)”
MethodProgestogen for preventing miscarriage
Haas, D. M., & Ramsey, P. S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003511.pub3 · Cited by 86
Progesterone Implantation in Habitual Abortion
Swyer, G. I. M., & Daley, D. (1953) · BMJ · doi:10.1136/bmj.1.4819.1073 · Cited by 86
Progestagen therapy for recurrent miscarriage
Szekeres‐Barthó, J., & Balasch, J. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm035 · Cited by 84
Cicinelli, E., Cignarelli, M., Sabatelli, S., Romano, F., Schonäuer, L. M., Padovano, R., & Einer‐Jensen, N. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00545-1 · Cited by 80 · cited 2×
“Our choice to use the vaginal route of administration was, therefore, rational to deliver a greater proportion of drug to the relevant site (the uterus) using the ‘first uterine pass’ effect.(36,37) Furthermore, studies that have used vaginal progesterone in the prevention of preterm birth have reported its effectiven…”
MethodLuteal phase support for assisted reproduction cycles
van der Linden, M., Buckingham, K., Farquhar, C., Kremer, J. A., & Metwally, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009154 · Cited by 71
McKenna, C., & Claxton, K. (2011) · Medical Decision Making · doi:10.1177/0272989x11399921 · Cited by 70 · cited 1×
“Future research might also consider estimating the value of further research using value of information analysis.(84,85) DOI: 10.”
BackgroundHABITUAL ABORTION. A CONTROLLED STUDY OF PROGESTATIONAL THERAPY.
LEVINE, L. (1964) · PubMed · Cited by 67
Endometrial factors in recurrent miscarriage
Li, T. C., Tuckerman, E. M., & Laird, S. M. (2002) · Human Reproduction Update · doi:10.1093/humupd/8.1.43 · Cited by 65
Self-citationLuteal insufficiency in first trimester
Shah, D., & Nagarajan, N. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.107834 · Cited by 62
Griffin, S., Welton, N. J., & Claxton, K. (2010) · Medical Decision Making · doi:10.1177/0272989x09344746 · Cited by 59
Progesterone for the prevention of preterm birth: A critical evaluation of evidence
Coomarasamy, A., Thangaratinam, S., Gee, H., & Khan, K. S. (2006) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2006.05.013 · Cited by 55 · cited 3×
“Furthermore, studies of vaginal progesterone in the prevention of preterm birth have shown its effectiveness when given via this route.(19,21,22) Therefore, we believe that any alternative preparation or route of administration is unlikely to result in a greater effect.”
BackgroundMethodSelf-citationHospital Costs and Quality of Life During 4 Years After Very Preterm Birth
Korvenranta, E., Linna, M., Rautava, L., Andersson, S., Gissler, M., Hallman, M., Häkkinen, U., Leipälä, J., Peltola, M., Tammela, O., et al. (2010) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpediatrics.2010.99 · Cited by 51 · cited 2×
“TABLE 13 Expected QALYs up to 4 years of age, by gestational age at birth, estimated from Korvenranta et al.(73)”
MethodInfluentialAn integrated view on the luteal phase: diagnosis and treatment in subfertility
Sonntag, B., & Ludwig, M. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04464.x · Cited by 51
Coomarasamy, A., Truchanowicz, E. G., & Rai, R. (2011) · BMJ · doi:10.1136/bmj.d1914 · Cited by 34
Self-citationUse of progestagens during early pregnancy.
Dante, G., Vaccaro, V., & Facchinetti, F. (2013) · PubMed · Cited by 29
The valuation of prenatal life in economic evaluations of perinatal interventions
Simon, J., Petrou, S., & Gray, A. (2008) · Health Economics · doi:10.1002/hec.1375 · Cited by 22 · cited 1×
“However, there remains unsettled debate about the valuation of prenatal life in economic evaluations.(72) The generic health gains in terms of QALYs are reported in Sensitivity analyses, Estimation of quality-adjusted life-years and costs beyond the trial end point.”
BackgroundUse of progestogens in pregnant and infertile patients
Özlü, T., Güngör, A. N. Ç., Dönmez, M. E., & Duran, B. (2012) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-012-2340-4 · Cited by 16
Mogli, G. (2013) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/11884_9 · Cited by 12
Baseline comparisons in clinical trials
Altman, D. G., & Doré, C. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91515-c · Cited by 8
Public and patient involvement
(2003) · Nursing Management · doi:10.7748/nm.10.5.31.s18 · Cited by 5
Research works printed but not linked: 25
- Regan, 2003, The Investigation and Treatment of Couples with Recurrent Miscarriage
- d-maps.com, United Kingdom/United Kingdom of Great Britain and Northern Ireland: Outlines, Nations, Color (White)
- d-maps.com, Netherlands/Koninkrijk der Nederlanden: Outline, Provinces, Color (White)
- US Food and Drug Administration Advisory Committee for Reproductive Health Drugs, 2003, Briefing Information for the September 29, 2003 Meeting of the Advisory Committee for Reproductive Health Drugs
- European Commission, 2003, Commission Directive 2003/94/EC of 8 October 2003
- European Commission, 2001, Commission Directive 2001/20/EC of 4 April 2001
- EudraLex, 2010, The Rules Governing Medicinal Products in the European Union, Volume 4: Guidelines for Good Manufacturing Practices for Medicinal Products for Human and Veterinary Use – Annex 13, Manufacture of Investigational Medicinal Products
- Datapharm, Utrogestan Vaginal 200 mg Capsules – Summary of Product Characteristics
- Joint Formulary Committee, 2014, British National Formulary
- Great Britain, 2006, The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006
- Royal Pharmaceutical Society of Great Britain, 2005, The Safe and Secure Handling of Medicines: A Team Approach
- National Pharmacy Clinical Trials Advisory Group, 2013, Professional Guidance on Pharmacy Services for Clinical Trials, Version 1
- Imperial College London/Imperial College Healthcare NHS Trust Joint Research Compliance Office, 2015, Recording Managing and Reporting Adverse Events in the UK Imperial College of Science Technology and Medicine, Version 7.0
- Medical Research Council/Department of Health, Clinical Trials Toolkit 2007. Work Stream 6: Pharmacovigilance (Updated 2012)
- European Commission, 2006, Detailed Guidance on the Collection, Verification and Presentation of Adverse Reaction Reports arising from Clinical Trials on Medicinal Products for Human Use: Revision 2
- Great Britain, 1998, Data Protection Act 1998
- Department of Health, 2003, Confidentiality: NHS Code of Practice
- Department of Health, The Caldicott Committee, 1997, Report on the Review of Patient-Identifiable Information
- Department of Health, 2005, Research Governance Framework for Health and Social Care, Second Edition
- Involve, 2009, Public Involvement in the Management for the Research Design Service
- Gardosi, 2013, Customised Weight Centile Calculator
- Department of Health, 2012, Reference Costs 2011–12
- National Collaborating Centre for Women’s and Children’s Health, 2012, Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management in Early Pregnancy of Ectopic Pregnancy and Miscarriage
- Maternal Critical Care Working Group, 2011, Providing Equity of Critical and Maternity Care for the Critically Ill Pregnant or Recently Pregnant Woman
- National Institute for Health and Care Excellence, 2013, Guide to the Methods of Technology Appraisal 2013
Cited by
Quenby, S., Gallos, I. D., Dhillon-Smith, R. K., Podesek, M., Stephenson, M. D., Fisher, J., Brosens, J. J., Brewin, J., Ramhorst, R., Lucas, E. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00682-6 · Cited by 1,560
Self-citationDodd, J. M., Jones, L., Flenady, V., Cincotta, R., & Crowther, C. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004947.pub3 · Cited by 331
Progesterone-Related Immune Modulation of Pregnancy and Labor
Shah, N. M., Lai, P. F., Imami, N., & Johnson, M. R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00198 · Cited by 217
Laharie, D., Bourreille, A., Branche, J., Allez, M., Bouhnik, Y., Filippi, J., Zerbib, F., Savoye, G., Vuitton, L., Moreau, J., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313060 · Cited by 160
Steroid hormones and pregnancy
Noyola-Martínez, N., Halhali, A., & Barrera, D. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1564742 · Cited by 158
“Regarding the prevention of miscarriages, the results of a randomized, double-blind, placebo-controlled and international multicenter study have demonstrated that vaginal micronized P4 administration in early pregnancy did not result in significant decrease in unexplained recurrent miscarriages as compared with placeb…”
Result
Metadata
- Authors
- Coomarasamy, A., Williams, H., Truchanowicz, E., Seed, P. T., Small, R., Quenby, S., Gupta, P., Dawood, F., Koot, Y. E., Atik, R. B., Bloemenkamp, K. W., Brady, R., Briley, A., Cavallaro, R., Cheong, Y. C., Chu, J., Eapen, A., Essex, H., Ewies, A., Hoek, A., Kaaijk, E. M., Koks, C. A., Li, T.-C., MacLean, M., Mol, B. W., Moore, J., Parrott, S., Ross, J. A., Sharpe, L., Stewart, J., Trépel, D., Vaithilingam, N., Farquharson, R. G., Kilby, M. D., Khalaf, Y., Goddijn, M., Regan, L., & Rai, R.
- Affiliations
- University of Birmingham (GB)
- St Thomas' Hospital (GB)
- Heart of England NHS Foundation Trust (GB)
- University of Warwick (GB)
- Liverpool Women's Hospital (GB)
- University Medical Center Utrecht (NL)
- The Miscarriage Association, Wakefield, UK
- Leiden University Medical Center (NL)
- St Mary's Hospital (GB)
- Princess Anne Hospital (GB)
- University of York (GB)
- Sandwell & West Birmingham Hospitals NHS Trust (GB)
- University Medical Center Groningen (NL)
- OLVG (NL)
- Máxima Medisch Centrum (NL)
- Royal Hallamshire Hospital (GB)
- University Hospital Crosshouse (GB)
- The University of Adelaide (AU)
- Nottingham University Hospitals NHS Trust (GB)
- King's College Hospital NHS Foundation Trust (GB)
- Royal Victoria Infirmary (GB)
- Queen Alexandra Hospital (GB)
- Guy's Hospital (GB)
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Coomarasamy, Arri
- ORCID
- Coomarasamy, Arri
- Williams, Helen
- Seed, Paul T
- Small, Rachel
- Quenby, Siobhan
- Gupta, Pratima
- Bloemenkamp, Kitty WM
- Briley, Annette
- Cheong, Ying C
- Chu, Justin
- Eapen, Abey
- Essex, Holly
- Ewies, Ayman
- Hoek, Annemieke
- Koks, Carolien A
- Li, Tin-Chiu
- MacLean, Marjory
- Mol, Ben W
- Parrott, Steve
- Ross, Jackie A
- Stewart, Jane
- Trépel, Dominic
- Kilby, Mark David
- Khalaf, Yacoub
- Goddijn, Mariëtte
- Venue
- Health Technology Assessment
- Published
- 2016-05
- Volume
- 20
- Issue
- 41
- Pages
- 1-92
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- PMC
- PMC4904188
- OpenAlex
- W2403936163
- Cited by
- 109
- References
- 63
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 12 · 2023: 15 · 2022: 9 · 2021: 15 · 2020: 8 · 2019: 13 · 2018: 7 · 2017: 13 · 2016: 1
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by-nc)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Health Technology Assessment programme (08/38/01)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Keywords
- progesterone therapy, unexplained recurrent spontaneous abortion, early pregnancy loss, Utrogestan, live birth rate, clinical pregnancy, ongoing pregnancy, cost-effectiveness, economic evaluation, congenital malformations, neonatal survival, resource utilization (health care), pregnancy loss prevention, spontaneous conception, PROMISE trial
- MeSH terms
- Congenital Abnormalities, Abortion, Habitual, Administration, Intravaginal, Adolescent, Adult, Cost-Benefit Analysis, Double-Blind Method, Female, Gestational Age, United Kingdom, Humans, Infant, Infant Mortality, Netherlands, Pregnancy, Pregnancy Outcome, Pregnancy Trimester, First, Progesterone, Quality-Adjusted Life Years, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.